Table 3.
Outcome parameters for different second-line regimens (n=44).
| Systemic second-line therapy (n=68) | N (%) | Median number of cycles (range) | ORR [%] | Median PFS [months] |
Median OS [months] |
|---|---|---|---|---|---|
| Systemic treatment total | 44 (64.7%) | 3 (1-6) | 47.2% | 3.1 | 5.5 |
| ACO | 20 (45.5%) | 3.5 (1-5) | 52.9% | 2.4 | 5.5 |
| Topotecan | 13 (29.5%) | 3 (1-6) | 22.2% | 2.4 | 5.0 |
| Cisplatinum-etoposide | 5 (11.4%) | 3 (1-4) | 60% | 3.5 | 6.7 |
| Carboplatinum-etoposide | 3 (6.8%) | 4 (4-6) | 100% | 9.3 | 17.6 |
| Docetaxel | 1 (2.3%) | 1 (1-1) | 0% | 0.39 | 1.25 |
| Dotatoc | 2 (4.5%) | 1.5 (1-2) | 0% | 2.7 | 5.9 |
| No systemic treatment | 24 (35.3%) | - | - | - | 2.4 |
ACO, adriamycin, cyclophosphamide and vincristine; ORR, overall response rate; OS, overall survival; PFS, progression-free survival